In today’s NewsFlash Roundup, gadgets, biotech manufacturing and, as always, fruit juices.
• Genzyme drug shortage aided by Israeli firm
The U.S. Food and Drug Administration has contacted Israel-based Protalix BioTherapeutics Inc. about the possibility of initiating a treatment protocol for use of its Phase 3 drug target for Gaucher’s disease. The drug has not yet been approved for use in the U.S. but would be used to blunt the effect that the Cerezyme shortage is having on patients, who have no other approved treatment options.
• NMT Medical eyes conservative plans amid slow sales
The Boston-based company (Nasdaq: NMTI) said revenue for the second quarter that ended June 30 will be around $3.2 million, down from the $3.8 million to $4.3 million predicted in May.
• From the print edition: Ocean Spray, Welch’s pursuing scientific claims of fruits
Ocean Spray Cranberries Inc. has won a patent for a method of extracting oil from the tiny seeds of cranberries, which the patent claims can be used for “treating or reducing the occurrence of breast cancer,” among other diseases. It’s a bold claim, but when asked if he believes the yellowish oil that smells and tastes faintly of cranberries could really have that power, inventor Wassef Nawar says, “Absolutely.”
• Gadget Review: What it’s like to live with the Palm Pre, iPhone 3GS
This month, beaten to the initial punch by the industry’s favored national reviewers, your friendly gadget columnist spent some serious time with two of the hottest gadgets of the year: the Palm Pre and the Apple Inc. iPhone 3GS. This review is not so much about what it’s like to go on a date or even a one-night stand with either smartphone. Rather, you’ll hopefully get a truer sense of what it’s like to own one; consider it a report after the onset of the seven-year itch, as measured in gadget lifetimes.
Posted by Brendan Lynch
Tags: Allston, FDA, gadgets, Genzyme, iPhone, NMT Medical, Ocean Spray, Palm Pre, Welch's
RSS Feeds
